Pfizer (NYSE:PFE) Earns Buy Rating from Guggenheim

Pfizer (NYSE:PFE)‘s stock had its “buy” rating reissued by equities research analysts at Guggenheim in a research note issued to investors on Monday,Benzinga reports. They currently have a $33.00 price target on the biopharmaceutical company’s stock. Guggenheim’s target price would suggest a potential upside of 28.13% from the stock’s current price.

PFE has been the topic of several other research reports. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of PFE opened at $25.76 on Monday. The firm has a 50-day moving average of $26.28 and a 200-day moving average of $27.72. The company has a market cap of $145.96 billion, a PE ratio of 18.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the firm earned $0.10 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer will post 2.95 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rakuten Securities Inc. grew its holdings in shares of Pfizer by 10.2% during the 4th quarter. Rakuten Securities Inc. now owns 29,424 shares of the biopharmaceutical company’s stock valued at $781,000 after purchasing an additional 2,734 shares during the last quarter. Avantax Advisory Services Inc. boosted its position in Pfizer by 5.1% in the fourth quarter. Avantax Advisory Services Inc. now owns 348,990 shares of the biopharmaceutical company’s stock valued at $9,259,000 after buying an additional 17,054 shares in the last quarter. Essential Planning LLC. acquired a new position in shares of Pfizer during the fourth quarter worth $5,695,000. Jupiter Asset Management Ltd. lifted its stake in shares of Pfizer by 589.6% in the 4th quarter. Jupiter Asset Management Ltd. now owns 746,509 shares of the biopharmaceutical company’s stock valued at $19,805,000 after acquiring an additional 638,259 shares during the last quarter. Finally, Hopwood Financial Services Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at $56,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.